Activity Outline FDA Drug Topics: FDA Drug Information Resources and Applicability to Health Care Professionals February 18, 2020 FDA

Activity Coordinator:

Kara Burke (Kara.Burke@fda.hhs.gov), Kimberly DeFronzo (Kimberly.Defronzo@fda.hhs.gov), Lesley Navin(Lesley.Navin@fda.hhs.gov),

Series Description

This series of educational webinars is designed to aid physicians, physician assistants, nurses, pharmacists, pharmacy technicians, certified public health professionals, other health care professionals, and students, to provide better patient care by knowing how to find relevant FDA regulatory information that will improve drug safety.

Lecture Description

This webinar will provide an orientation to drug information resources on the FDA website including drug shortages, drug recalls, adverse event reporting, and product labeling. Health care professionals will learn how these drug information resources can be used in their practice to locate information that improves patient care.

References

- CDER Division of Drug Information Website: https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/cder-division-drug-information.
- Drugs@FDA: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm.
- MedWatch: https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program.
- Drug Shortages: https://www.fda.gov/drugs/drug-safety-and-availability/drug-shortages.
- Recalls, Market Withdrawals, & Safety Alerts: https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts.
- Drug Safety Communications: https://www.fda.gov/drugs/drug-safety-and-availability/drug-safety-communications.

Series Objectives

- Explain how to utilize FDA's drug information, medication safety resources, and regulatory guidance, to improve delivery of patient care and optimize outcomes.
- Describe and inform health care providers of recent labeling, policy and regulatory changes which would impact prescribing and medication management to optimize patient care.

Learning Objectives After completion of this activity, the participant will be able to:

- Identify drug information resources for HCPs to stay informed on FDA actions, decisions and initiatives.
- Demonstrate the use and application of these resources for common health-related inquiries.
- Discuss non-traditional drug information resources social media, podcasts, and videos.

Target Audience

This activity is intended for physicians, pharmacists, pharmacy technicians, nurses, CPH - certified public health, and physicians assistants.

Agenda

Lecture 1 February 18, 2020

Time	Торіс	Speaker
1:00 - 2:00 PM		Sandra Bai, PharmD

Continuing Education Accreditation



In support of improving patient care, FDA Center for Drug Evaluation and Research is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.



This activity was planned by and for the healthcare team, and learners will receive 1 Interprofessional Continuing Education (IPCE) credit(s) for learning and change.

CME

FDA Center for Drug Evaluation and Research designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credit(s)*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CPE

This knowledge-based activity has been assigned ACPE Universal Activity Number JA0002895-0000-20-006-L04-P, and ACPE Universal Activity Number JA0002895-0000-20-006-L04-T for 1.00 contact hour(s).

CNE

FDA Center for Drug Evaluation and Research designates this activity for 1.00 contact hour(s).

AAPA

This activity is designated for 1.00 AAPA Category 1 CME credits. FDA Center for Drug Evaluation and Research has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. PAs should only claim credit commensurate with the extent of their participation.

Requirements for Receiving CE Credit

Physicians, physician assistants, pharmacists, nurses, pharmacist techs, and those claiming non-physician CME: participants must attest to their attendance and complete the final activity evaluation via the CE Portal (ceportal.fda.gov). For multi-day activities, participants must attest to their attendance and complete the faculty evaluation each day. Final activity evaluations must be completed within two weeks after the activity - no exceptions.

Pharmacists will need their NABP e-profile ID number as well as their DOB in MMDD format in order to claim CE credit.

Important Note regarding completion of evaluations and receiving credit

Attendees have 14 days from the last day of the activity to log in, complete the required evaluation(s) and attest to your attendance to claim credit. Physicians, physician assistants, and nurses may then view/print statement of credit. Pharmacists should log into the CPE monitor 10 weeks after the last session of the activity to obtain their CE credit.

Disclosure

Faculty

■ Bai, Sandra, PharmD, Drug Information Specialist, FDA - nothing to disclose

Planning Committee

- Burke, Kara, PharmD, Team Leader/Pharmacist, FDA/CDER/OCOMM/DDI nothing to disclose
- □ Cao, Christian, MPAS, PA-C, Safety Evaluator Team Leader, FDA/CDER/OSE/DPV nothing to disclose

- □ DeFronzo, Kimberly, RPh, MS, MBA, Consumer Safety Officer, FDA/CDER/OCOMM/DDI nothing to disclose □ Kapoor, Rama, MD, Medical Officer, FDA nothing to disclose
- Navin, Lesley, RN, MSN, Consumer Safety Officer, FDA/CDER/DDI nothing to disclose

CE Consultation and Accreditation Team

- Lisa Thompson, MSHA, MBA, CE Consultant, FDA/CDER/OEP/DLOD nothing to disclose
- □ Zawalick, Karen, CE Team Leader, FDA/CDER/OEP/DLOD nothing to disclose

Registration Fee and Refunds

Registration is complimentary, therefore refunds are not applicable.